Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

AVXL RSS Feed
Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: RedShoulder, Steady_T, mrplmer, 123tom, kund, boi568
Search This Board: 
Last Post: 1/28/2022 7:25:50 AM - Followers: 940 - Board type: Free - Posts Today: 18

Anavex Life Sciences Corp (AVXL)



Company website:  http://www.anavex.com/
 
 Nasdaq 
 
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA
1-844-689-3939

 
CIK:  0001314052
 

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL

.
 
Management:  https://www.anavex.com/our-team/
 
Pipeline:  https://www.anavex.com/pipeline/

Patent Info: 
https://www.anavex.com/?s=patents

Clinical Trials:  https://clinicaltrials.gov/ct2/results?term=Anavex+Life+Sciences&Search=Search
 
Recent News:  https://finance.yahoo.com/q?s=avxl&ql=1

Company News Releases:  http://anavex.com/news/
 
Filings:  https://www.sec.gov/cgi-bin/browse-edgar?company=anavex&owner=exclude&action=getcompany
 
Share Structure:  See SEC filings
 
Investor Relations:  ir@anavex.com

Marketing Details:  https://www.anavex.com/investor-material/events/

 



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
AVXL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Anavex Life Sciences (AVXL) Gets a Buy Rating from H.C. Wainwright 01/11/2022 01:45:12 AM
AVXL News: Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71 01/10/2022 02:00:00 AM
AVXL News: Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer 01/06/2022 02:00:00 AM
AVXL News: Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference 01/05/2022 02:00:00 AM
AVXL News: Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference 12/14/2021 02:00:00 AM
PostSubject
#340923  Sticky Note Good scrutiny and understanding of Anavex science. falconer66a 12/22/21 03:51:30 PM
#338754  Sticky Note Anavex Company Overview (Current as of 5 Dec 2021) MayoMobile 12/05/21 04:46:09 AM
#337724  Sticky Note Compiled DD and recent posts: XenaLives 11/26/21 10:28:20 PM
#316438  Sticky Note Anavex 2-73-RS-001 Adult Low Dose Rett Trial (U.S.) MayoMobile 06/21/21 08:17:03 PM
#347058   Investor: OK, and thanks for that! sab63090 01/28/22 07:45:30 AM
#347057   Georgeejil Appreciate your comments, too! Sometimes I skim sab63090 01/28/22 07:25:50 AM
#347056   Steady T sab63090 01/28/22 07:21:46 AM
#347055   I've been here July 2015. I think I 98beamer 01/28/22 07:18:40 AM
#347054   Meanwhile...the stock is going to continue to tank. mike_dotcom 01/28/22 07:09:25 AM
#347053   Come Monday, it'll be alright.... 98beamer 01/28/22 07:08:39 AM
#347052   The rolling NDA is perfect for aligning all WolfofMia 01/28/22 07:07:26 AM
#347051   If only we had someone on board with jimmy_mcyoloswag 01/28/22 07:06:49 AM
#347050   The endpoints have not changed to RSBQ and Investor2014 01/28/22 07:02:25 AM
#347049   I’m still a little confused on how they hnbadger1 01/28/22 06:56:35 AM
#347048   Really Investor? WolfofMia 01/28/22 06:48:10 AM
#347047   For all the reasons I gave in detail boi568 01/28/22 03:24:57 AM
#347045   Gernee, That thought crossed my mind. I considered Steady_T 01/28/22 01:27:04 AM
#347044   Due to the Excellence trial expansion and positive Gernee20 01/28/22 01:10:48 AM
#347043   MOTHER OFF ALL NEWS IS AROUND THE CORNER longtermbeliever 01/28/22 12:15:22 AM
#347042   if shorty don't cover tomorrow when will they longtermbeliever 01/28/22 12:08:11 AM
#347041   "THESE CHANGES CAN ONLY HAPPEN WITH THE BLESSINGS'--thank plexrec 01/28/22 12:01:00 AM
#347040   The Biogen and Biomarker syndrome is bringing in Talon38 01/27/22 11:42:26 PM
#347039   Hi Fitzy Foodman1291 01/27/22 11:16:32 PM
#347038   Or P4 JWC3 01/27/22 11:13:05 PM
#347037   AA-227733 - Every picture tells a story. C-mon bb8675309 01/27/22 11:02:28 PM
#347036   Clinicaltrials.gov website for the Excellence trial has not Steady_T 01/27/22 10:54:50 PM
#347035   ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE) georgejjl 01/27/22 10:45:49 PM
#347034   Bingo! catdaddy 01/27/22 10:36:56 PM
#347033   George, the corporate slide #9 says Excellence is meds4life 01/27/22 10:36:45 PM
#347032   It seems that the delay in reporting Avatar sokol 01/27/22 10:30:30 PM
#347031   Christopher Missling -- President and Chief Executive Officer georgejjl 01/27/22 10:25:37 PM
#347030   Agreed. Thank you. sokol 01/27/22 10:18:44 PM
#347029   Here's Doc's January 12 remark on RSBQ in boi568 01/27/22 10:10:13 PM
#347028   Now what if the FDA accepts SIGMAR1 mRNA kevindenver 01/27/22 10:09:10 PM
#347027   Maybe we will receive data next week. sokol 01/27/22 10:06:26 PM
#347026   The predictive biomarker of response established with SIGMAR1 georgejjl 01/27/22 09:53:50 PM
#347025   I think the change in the RSBQ from boi568 01/27/22 09:49:05 PM
#347024   Making it pivotal is a big deal and Steady_T 01/27/22 09:44:11 PM
#347023   Top-line data AVATAR: Potentially pivotal Phase 3 adult georgejjl 01/27/22 09:44:04 PM
#347022   What about an accelerated approval after the FDA kevindenver 01/27/22 09:38:21 PM
#347021   Thank you George. I miss read the updates Steady_T 01/27/22 09:35:04 PM
#347020   TLD ... Top Line Data. Steady_T 01/27/22 09:33:19 PM
#347019   As I understand it that does not give Steady_T 01/27/22 09:32:43 PM
#347018  Restored Steady_T, There are just two primary endpoints for georgejjl 01/27/22 09:29:04 PM
#347017   At least now we have a pretty good hnbadger1 01/27/22 09:18:16 PM
#347016   "TLD?" falconer66a 01/27/22 09:15:41 PM
#347015   Yes the Avatar trial has finished dosing for Steady_T 01/27/22 09:07:27 PM
#347014   Good points. Doesn’t it also give us the Pazzo1212 01/27/22 09:01:55 PM
#347012   ANAVEX2-73 Study in Patients With Rett Syndrome (AVATAR) georgejjl 01/27/22 08:44:58 PM
#347010   LOL ExtremelyBullishZig 01/27/22 07:59:53 PM
#347009   Steady is onto it! xodcode 01/27/22 07:55:34 PM
#347008   I don't believe he's answered yet, has he Growingpain? catdaddy 01/27/22 07:54:42 PM
#347007   Do junior analysts check the .gov website every ignatiusrielly35 01/27/22 07:47:56 PM
#347006   Interesting possibilities. nidan7500 01/27/22 07:18:47 PM
PostSubject
Consent Preferences